Innovation Pharmaceuticals Inc (IPIX)

[TOB]

Very impressive and positive CTIX PR and presentation!

Kevetrin is essentially a near guaranteed successful Phase I at this point. Only unexpected SAEs could change this, and there is nothing to date suggest this is likely.

Link to 1/15/2014 PR

By the timing of the move to 7th cohort, it appears there have been ZERO Dose Limiting Toxicities in any cohort including the 6th cohort, and Kevetrin is now dosing safely well into the range believed to be effective. (Phase 2 or 2/3 will zero in on the effective dose and frequency once this Phase 1 safety and dose escalation likely concludes successfully)

University of Bologna has apparently seen the successful safety and PK data on the dose of Kevetrin they are targeting for the combination study. Excellent, so the combination trial will now proceed. IMO, based upon the interest by University of Bologna and Beth Israel Deaconess, this will be a big part of the Kevetrin story; combinations with the Kevetrin making a big difference.

Amazing how many of these very sick patients are having multiple cycles of Kevetrin. Astonishing really, and not at all normal for this sort of study with such a sick patient group. Obviously Kevetrin is nothing like other chemotherapeutic drugs which are highly toxic and can only be administered in very limited number of cycles. Kevetrin is so far proven safe for multiple dosing cycles.

Tumour REGRESSION (SHRINKAGE) in one patient is a very exiting preliminary indication of EFFICACY to add to the other signs of cancer treatment EFFICACY for Kevetrin that have been reported. All this will, of course, require confirmation with a larger, statistically significant cohort size in the follow-on phases.

A follow-on phase clinical trial of Kevetrin really looks like a slam-dunk at this point. It is already a go with the combination trial at University of Bologna.

Great news on Brilacidin and Prurisol progress towards clinical trials as well, though I personally remain more fascinated by Kevetrin. Cellceutix having two or three drugs in Clinical Trials in 2014 will be a remarkable development.

As far as the market reaction so far... meh. A few hundred thousand shares and a small, 1 digit percentage move in either direction is just noise to me in the longer run. But important for scalpers and morale of longs I suppose. Buy the rumour and sell the news remains in effect for now.